Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
09
2020
accepted:
21
06
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Bioavailable 25-hydroxyvitamin D (25OHD) may be a better indicator of vitamin D sufficiency than total 25OHD. This report describes a novel assay for measuring serum bioavailable 25OHD. We developed an assay for 25OHD % bioavailability based on competitive binding of 25OHD tracer between vitamin D-binding protein (DBP)-coated affinity chromatography beads and serum DBP. Bioavailable 25OHD, total 25OHD, albumin, and DBP protein concentrations were measured in 89 samples from hospitalized patients and 42 healthy controls to determine how the DBP binding assay responds to differences in concentrations of DBP and compares to calculated bioavailable 25OHD values. DBP binding assay showed a linear relationship between DBP-bound 25OHD tracer recovered from bead supernatant and DBP calibrator concentrations (y = 0.0017x +0.731, R2 = 0.9961, p<0.001). Inversion of this relationship allowed interpolation of DBP binding equivalents based upon 25OHD tracer recovered. The relationship between DBP binding equivalents and % bioavailability fits a non-linear curve, allowing calculation of % bioavailable 25OHD from DBP binding equivalents (y = 10.625x-0.817, R2 = 0.9961, p<0.001). In hospitalized patient samples, there were linear relationships between DBP protein concentrations and DBP binding equivalents (y = 0.7905x + 59.82, R2 = 0.8597, p<0.001), between measured vs. calculated % bioavailability (y = 0.9528 + 0.0357, R2 = 0.7200, p<0.001), and between absolute concentrations of measured vs. calculated bioavailable 25OHD (y = 1.2403 + 0.1221, R2 = 0.8913, p<0.001). The DBP-binding assay for bioavailable 25OHD shows expected changes in 25OHD % bioavailability in response to changes in DBP concentrations and concordance with calculated bioavailable 25OHD concentrations.
Sections du résumé
BACKGROUND
Bioavailable 25-hydroxyvitamin D (25OHD) may be a better indicator of vitamin D sufficiency than total 25OHD. This report describes a novel assay for measuring serum bioavailable 25OHD.
METHODS
We developed an assay for 25OHD % bioavailability based on competitive binding of 25OHD tracer between vitamin D-binding protein (DBP)-coated affinity chromatography beads and serum DBP. Bioavailable 25OHD, total 25OHD, albumin, and DBP protein concentrations were measured in 89 samples from hospitalized patients and 42 healthy controls to determine how the DBP binding assay responds to differences in concentrations of DBP and compares to calculated bioavailable 25OHD values.
RESULTS
DBP binding assay showed a linear relationship between DBP-bound 25OHD tracer recovered from bead supernatant and DBP calibrator concentrations (y = 0.0017x +0.731, R2 = 0.9961, p<0.001). Inversion of this relationship allowed interpolation of DBP binding equivalents based upon 25OHD tracer recovered. The relationship between DBP binding equivalents and % bioavailability fits a non-linear curve, allowing calculation of % bioavailable 25OHD from DBP binding equivalents (y = 10.625x-0.817, R2 = 0.9961, p<0.001). In hospitalized patient samples, there were linear relationships between DBP protein concentrations and DBP binding equivalents (y = 0.7905x + 59.82, R2 = 0.8597, p<0.001), between measured vs. calculated % bioavailability (y = 0.9528 + 0.0357, R2 = 0.7200, p<0.001), and between absolute concentrations of measured vs. calculated bioavailable 25OHD (y = 1.2403 + 0.1221, R2 = 0.8913, p<0.001).
CONCLUSIONS
The DBP-binding assay for bioavailable 25OHD shows expected changes in 25OHD % bioavailability in response to changes in DBP concentrations and concordance with calculated bioavailable 25OHD concentrations.
Identifiants
pubmed: 34242315
doi: 10.1371/journal.pone.0254158
pii: PONE-D-20-28763
pmc: PMC8270209
doi:
Substances chimiques
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0254158Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK094486
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133399
Pays : United States
Déclaration de conflit d'intérêts
Four of the authors on this manuscript (AB, RT, AK, and IB) are co-authors on a patent (WO2014179737A3, “Assays and methods of treatment relating to vitamin D insufficiency”). At the time of submission of this revised manuscript, this patent has not been licensed or otherwise used for commercial use by any of the authors or their respective institutions. None of the authors have any employment, consultancy, products in development, modified products, or other financial relationships related to the assay described in this manuscript. We have reviewed the PLOS ONE policies on sharing data and materials. This does not alter our alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Electrophoresis. 1990 Jun;11(6):478-83
pubmed: 2394211
Inflamm Res. 2001 Jan;50(1):39-43
pubmed: 11235020
J Bone Miner Res. 2011 Jul;26(7):1609-16
pubmed: 21416506
Best Pract Res Clin Endocrinol Metab. 2013 Oct;27(5):631-45
pubmed: 24094635
Kidney Int. 2012 Jul;82(1):84-9
pubmed: 22398410
N Engl J Med. 2019 Jun 27;380(26):2584-2585
pubmed: 31242375
Clin Chem. 1985 Apr;31(4):517-22
pubmed: 3978781
Clin Chem. 2015 Jun;61(6):877-84
pubmed: 25922442
Proc Natl Acad Sci U S A. 1975 Jun;72(6):2076-80
pubmed: 49052
Clin Chem. 2006 Jul;52(7):1247-53
pubmed: 16709624
Obes Surg. 2016 Nov;26(11):2732-2737
pubmed: 27116295
J Steroid Biochem. 1989 Jan;32(1A):59-63
pubmed: 2913402
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
Clin Chem. 2016 Dec;62(12):1647-1653
pubmed: 27694392
J Steroid Biochem Mol Biol. 2019 Feb;186:79-88
pubmed: 30278215
N Engl J Med. 2019 Jun 27;380(26):2582-2583
pubmed: 31242372
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3278-3288
pubmed: 29955795
J Crit Care. 2018 Feb;43:294-299
pubmed: 28968524
JAMA. 2014 Oct 15;312(15):1520-30
pubmed: 25268295
J Intern Med. 2019 Dec;286(6):651-659
pubmed: 31215092
J Clin Endocrinol Metab. 2017 Jan 1;102(1):100-110
pubmed: 27768857
Anal Biochem. 1998 May 1;258(2):176-83
pubmed: 9570827
J Clin Invest. 1999 Jan;103(2):239-51
pubmed: 9916136
J Steroid Biochem Mol Biol. 2017 Oct;173:105-116
pubmed: 28093353
Cell Biochem Funct. 2012 Aug;30(6):445-56
pubmed: 22528806
J Clin Endocrinol Metab. 1986 Oct;63(4):954-9
pubmed: 3745408
J AOAC Int. 2017 Sep 1;100(5):1318-1322
pubmed: 28492143
N Engl J Med. 2013 Nov 21;369(21):1991-2000
pubmed: 24256378
N Engl J Med. 2014 Feb 27;370(9):879
pubmed: 24571765
Nephrology (Carlton). 2016 Jun;21(6):483-9
pubmed: 26428957
Osteoporos Int. 2017 Mar;28(3):1013-1020
pubmed: 27826645
J Bone Miner Res. 2016 Jun;31(6):1128-36
pubmed: 27250744
N Engl J Med. 2014 Feb 27;370(9):878-9
pubmed: 24571764
Osteoporos Int. 2016 Feb;27(2):617-26
pubmed: 26359185
Intensive Care Med. 2015 Nov;41(11):1961-4
pubmed: 26142054
N Engl J Med. 2019 Mar 21;380(12):1150-1157
pubmed: 30893535
Endocr Rev. 1989 Aug;10(3):232-74
pubmed: 2673754
Ann Intern Med. 1995 Apr 1;122(7):511-3
pubmed: 7872586
Front Endocrinol (Lausanne). 2019 May 28;10:317
pubmed: 31191450
Hum Genet. 1993 Sep;92(2):183-8
pubmed: 8370586
Circ Res. 2018 Sep 28;123(8):996-1007
pubmed: 30355032